人类表皮生长因子受体2表达在妇科血清癌和初步分析其特征在患者后的新辅助化疗后的患者
Lili Liu1, Naixuan Cheng1, Fangzhou Kong1
1Department of Pathology, Peking University People's Hospital, Beijing, China.
人类表皮生长因子受体2 (HER2) 阳性和低表达存在于子宫血清癌 (USC) 和卵巢高度血清癌 (HGSC). HER2 状态影响预后,针对性治疗对 HER2 阳性和 HER2 低患者都有潜在的益处.
科学领域:
- 妇科瘤学 妇科瘤学
- 病理学 病理学 病理学
- 分子诊断学 分子诊断
背景情况:
- 子宫血清癌 (USC) 和卵巢高度血清癌 (HGSC) 是一种侵袭性的妇科恶性瘤.
- 人类表皮生长因子受体2 (HER2) 是几种癌症的关键治疗标.
- 在USC和HGSC中HER2的作用和检测需要进一步澄清.
研究的目的:
- 在USC和HGSC研究HER2蛋白表达和基因放大.
- 为了确定HER2阳性和HER2-低表达的频率.
- 评估不同的HER2解释标准及其预后影响.
主要方法:
- 追溯分析了51起美国联邦法院和165起高加索法院案件.
- 免疫组织化学 (IHC) 用于HER2蛋白表达.
- 在HER2基因放大过程中进行光在位杂交 (FISH).
- 两个HER2解释指南的比较:ASCO/CAP和ISGyP.
主要成果:
- 在USC的29.4%和HGSC的4.9%-7.0%病例中发现了HER2基因放大.
- 与ASCO/CAP相比,ISGyP标准发现了更多的HER2低表达病例.
- 在HGSC中,HER2阳性与整体存活率较差有关,并在新辅助化疗后预测较短的无进展存活率.
结论:
- 显著的USC和HGSC患者的一个小组表现出HER2阳性或HER2-低表达.
- ISGyP标准提供了对HER2状态的更全面的评估,特别是对于HER2低的病例.
- HER2状态是HGSC的相关预后标志物,可以指导治疗决策,包括针对HER2低患者的新型抗体药物联合疗法.
更多相关视频
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
07:19Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids
Published on: January 6, 2023
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
